Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
Open Access
- 19 March 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Radiation Oncology
- Vol. 8 (1), 65
- https://doi.org/10.1186/1748-717x-8-65
Abstract
The cytotoxicity of radiotherapy and chemotherapy can be enhanced by modulating DNA repair. PARP is a family of enzymes required for an efficient base-excision repair of DNA single-strand breaks and inhibition of PARP can prevent the repair of these lesions. The current study investigates the trimodal combination of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in glioblastoma (GBM) cells.Keywords
This publication has 34 references indexed in Scilit:
- In VitroEvaluation of Combined Temozolomide and Radiotherapy Using X Rays and High-Linear Energy Transfer Radiation for GlioblastomaRadiation Research, 2012
- Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activityMolecular Cancer Therapeutics, 2009
- Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft linesMolecular Cancer Therapeutics, 2009
- DNA repair pathways as targets for cancer therapyNature Reviews Cancer, 2008
- A scanning focussed vertical ion nanobeam: A new UK facility for cell irradiation and analysisNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms, 2007
- Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer ModelsClinical Cancer Research, 2007
- ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsClinical Cancer Research, 2007
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Years of life lost (YLL) from cancer is an important measure of population burden — and should be considered when allocating research fundsBritish Journal of Cancer, 2005